Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > On the Radar In Japan :-}

<< Previous

Bullboard Posts

Next >>

Comment by wildbird1on Mar 25, 2024 8:06am

343 Views

Post# 35950225

RE:On the Radar In Japan :-}

''This groundbreaking technology innovates NMIBC treatment and marks a transformative shift in medical technology paradigms''.
You have to love this quote!

We talk a lot about TLT getting BTD approval and one large pharma deal.

But what would happen to the SP, if Dr.Lbiati was to sign more than one large pharma deal.
-One in North-America.
-A few months later one in Europe.
-A few months later one in Asia.

Nothing wrong with dreaming( for now let's start with just one).

Oden6570 wrote:

TLD-1433, combined with the TLC-3200 medical laser system, pioneers a personalized Ruthenium-based PhotoDynamic compound for BCG-unresponsive NMIBC, including CIS and papillary Ta or T1 tumors. This groundbreaking technology innovates NMIBC treatment and marks a transformative shift in medical technology paradigms.

Japan Non-muscle Invasive Bladder Cancer - Market Insights, Epidemiology, and Market Forecast - 2032 (researchandmarkets.com)